Category Archives: Physiology

Join the 5% Healthier Initiative | E-News | West Virginia University – WVU ENews

HSC faculty and staff are invited to register for the WVU Exercise Physiology's 5% Healthier Initiative. This training program will help participants get healthier by working one-on-one with a student coach who will provide support, accountability and personalized exercise coaching.

Those looking for something new to facilitate health and wellbeing during this time should consider this homegrown program at HSC.

Find more information and register for this program.

For questions, contact Emily Reinhart at erreinhart@mix.wvu.edu.

See the original post here:
Join the 5% Healthier Initiative | E-News | West Virginia University - WVU ENews

Newly Recruited Scientists Bring Innovative Imaging Technology to YSM – Yale School of Medicine

Two scientists who are pioneering innovators of the imaging technology known as enhanced Focused Ion Beam Scanning Electron Microscopy (FIB-SEM) will be coming to Yale School of Medicine. C. Shan Xu, PhD, will join the faculty in the Department of Cellular and Molecular Physiology and Song Pang, MS, will lead collaborations using this technology via a FIB-SEM Collaboration Core. The arrival of these two outstanding scientists will allow us to build upon Yales strengths in imaging and advance as a leader in cutting-edge imaging technology, says Nancy J. Brown, MD, Jean and David W. Wallace Dean of Medicine. Their expertise will have a major impact on basic science discoveries that will deepen our understanding of human biology.

Almost 500 years ago Andreas Vesalius published De Humani Corporis Fabrica Libri Septem, a revolutionary anatomy text that was the first to contain illustrations of the human body based on observations from dissections. Vesalius instinctively knew that the human body could only be understood by developing a three-dimensional appreciation of how its tissues and organs fit together. While he was limited to what could be perceived by the human eye, today, sophisticated microscopy allows us to view the three-dimensional structure of tissues and organs at the cellular and subcellular level. This is fundamental to achieving scientific breakthroughs that drive medical advances. In 2018, Yale acquired the only focused ion beam-scanning electron microscope in the region. FIB-SEM opens up the possibility of examining cellular structuresand how they relate to one anotherin three dimensions. FIB-SEM is a beautiful tool that helps us connect form to function, says Michael Caplan, PhD 87, MD 87, chair and C.N.H. Long Professor of Cellular and Molecular Physiology.

But the technology has limitations. It works as a kind of micro-machining tool that uses high-energy gallium ions to etch away ultra-thin layers of tissue that have been embedded in plastic, generating a series of images that must be painstakingly aligned and combined to create the final image. Its a slow process in which only small volumes of tissue can be imaged over a period of several days. To image larger volumes would require operating for much longer periods of time, during which the process is inevitably interrupted due to ion source replenishment and system glitches that lead to defects in the final image.

At the Janelia Research Campus of Howard Hughes Medical Institute, where Xu currently directs FIB-SEM Technologies and Pang is a research application scientist in the FIB-SEM Technology Division, Xu is the lead inventor of enhanced FIB-SEM. This technology expands the imageable volume by orders of magnitude, achieves 3D isotropic resolutions of eight and four nanometersabout one 25,000th of the width of a hairand improves its stability to reach 100% effective reliability. These advances enable the platform to continuously run for months or years instead of days and to generate images that, when assembled, are free of defects.

Enhanced FIB-SEM has enabled discoveries in tissue biology, cell biology, and the connectomethe system of neural pathways in the brain. Recently, it enabled an open-access high-resolution 3D atlas of whole cells and tissues, from cancer and immune cells to mouse pancreatic islets and Drosophila neural tissues. It was also used to image the circuitry of a large portion of the Drosophila brain, the largest and most detailed connectome to date. With 25,000 neurons and 4,00 cell types, it took two years and two microscopes to complete. The technology has continued to advance and allowed for the image acquisition of the entire Drosophila central nervous system, consisting of approximately 200,000 neurons, a yearlong process involving eight FIB-SEMs running in parallel.

Enhanced FIB-SEM will build upon and complement YSMs existing strength in FIB-SEM, which was established within the Center for Cellular and Molecular Imaging (CCMI) Electron Microscopy Facility by its director, Xinran Liu, MD, PhD, who expertly oversees its operation. Yale investigators will have the opportunity to apply these technologies to an extraordinarily diverse palette of tissues and scientific questions. Pang and Xu are already collaborating with Yale researchers to explore structures that had never before been studied with such powerful imaging technology.

With 29 years of experience in technology invention and application development, Xu holds 22 patents and is actively involved in teaching courses and leading workshops on volume electron microscopy worldwide. At Yale School of Medicine, he plans to develop the next generation of FIB-SEM technology, aiming to further advance the 3D isotropic resolution and use cryogenic techniques to image cells in their native state (by cooling them to very low temperatures instead of fixing them in plastic) but at much larger volumes. Xu will also work to develop FIB-SEM into a tool that can report on much more than a specimens physical appearance. Electron microscopy generates black and white images that illustrate the structure of a specimen but provide little information on its chemical composition. By redesigning the ways in which the images are collected, he hopes to unlock a previously inaccessible trove of biochemical detail.

These improvements will allow scientists to better study the structure and relationships of molecules within the cellular environment. Scientists now understand that organelles within cells are in physical contact and communicate with one another, which affects the regulation of their function. Enhanced FIB-SEM allows us to see those contacts and how they change as a result of different physiological stimuli, says Caplan. It will allow us to understand not only at a structural level how cells are organized, but also how that organization is shaped by and responds to stimuli.

The arrival of Xu and Pang continues not only the legacy of Vesalius, but also Yale School of Medicines tradition of using imaging as a powerful tool for discovery. In the 1950s, George Paladea Nobel laureate who is widely considered the father of modern cell biology and was the founding chair of the Department of Cell Biologyrecognized the power of electron microscopy. It wasnt lost on Xu or Caplan, for whom Palade served as a thesis advisor, that Palade would have been awed by the images generated by enhanced FIB-SEM. Palade subscribed to the notion that form follows function, making Physiology, which connects the properties of molecules to the properties of higher order biological structures, the logical home for Xu and Pang.

Xu and Pang are eager to bring enhanced FIB-SEM to Yale for the opportunity to work with human tissue to create a connection between basic science and clinical models and develop robust datasets that researchers can mine. We can combine this cutting-edge state-of-the-art technology with Yales world class scientists who can utilize it to enable their amazing discoveries, said Xu. Added Pang, What we really want to do is to cultivate a rich ecosystem from the image to data analysis to discovery.

Read the original here:
Newly Recruited Scientists Bring Innovative Imaging Technology to YSM - Yale School of Medicine

Biochemist Carrie Partch honored by the National Academy of Sciences – UC Santa Cruz

Carrie Partch, professor of chemistry and biochemistry at UC Santa Cruz, will be honored by the National Academy of Sciences (NAS) with the 2022 NAS Award in Molecular Biology for her contributions to the molecular understanding of circadian rhythms.

Partchs transformative work has shed light on the protein-based signaling mechanisms and structural assemblies that give rise to daily cycles known as circadian rhythms in most living things. These daily cycles affect virtually every aspect of our physiology and are driven by the interactions of clock proteins in our cells.

Partchs studies reveal protein dynamics and interactions at the core of molecular circadian timing mechanisms in both mammals and in cyanobacteria. Her unique approach to the field combining biochemistry, molecular biophysics, and structural biology has provided a deeper mechanistic understanding of how these clocks function at the molecular level.

The NAS Award in Molecular Biology is presented with a medal and a $25,000 prize.

Partch is among 18 individuals being honored this year with NAS awards recognizing their extraordinary scientific achievements in a wide range of fields spanning the physical, biological, social, and medical sciences. The winners will be honored in a ceremony during the National Academy of Sciences' 159th annual meeting in April.

The National Academy of Sciences is a private, nonprofit institution that was established under a congressional charter signed by President Abraham Lincoln in 1863. It recognizes achievement in science by election to membership, andwith the National Academy of Engineering and the National Academy of Medicineprovides science, engineering, and health policy advice to the federal government and other organizations.

See the original post here:
Biochemist Carrie Partch honored by the National Academy of Sciences - UC Santa Cruz

Recipients of 2022 Alumni Awards announced – The Baylor Lariat

By Matt Kyle | Staff Writer

Last week, Baylor University announced the recipients of the 2022 Alumni Awards. The university also announced that a celebration recognizing the recipients and honoring the impact of alumni around the world will be held on Feb. 18.

This years recipients include Thasunda Brown Duckett, MBA 01 as the Alumni of the Year and Alex Le Roux, BS 15 as the Young Alumni of the Year. Rebekah Naylor, BA 64, MD was the recipient of the Pro Ecclesia Medal of Service, and Susan Peters, BA 86 received the Pro Texana Medal of Service. Giancarlo Guerrero, BM 91 and Chris Charles Scott III, BA 04 each received the Medal of Service for Contributions to the Professions. Fran George was named the Merrie Beckham Alumni By Choice of the Year.

Amy Armstrong, associate vice president of alumni engagement, said the awards are meant to recognize graduates who excel in their field and have an impact on the world.

Baylor alumni do amazing things, Armstrong said. They come to Baylor, they learn, they study and then they go out into the world. Its our way to celebrate some of those alumni who are going above and beyond and have great success on all different kinds of levels whether its business or nonprofit within the Christian values.

Armstrong said the celebration in February will include a banquet dinner where President Linda Livingstone will present each of the recipients with a medal. Armstrong also said Baylors social media and web pages will share stories about each of the award recipients and their accomplishments throughout the spring, and the Baylor Magazine will feature similar stories about the recipients.

Alumna of the Year Duckett is the president and CEO of the Teachers Insurance and Annuity Association of America a Fortune 100 financial services organization. Duckett was included in Fortunes and Forbes list of the Most Powerful Women in 2021 and serves on the board of trustees for Sesame Workshop and on the board of directors for Nike. Inc, Robert F. Kennedy Human Rights, the University of Houston Board of Visitors and the Deans Advisory Board for Baylor Universitys Hankamer School of Business. In 2013, she founded the Otis and Rosie Brown Foundation in honor of her parents.

Naylor, recipient of the Pro Ecclesia Medal of Service, is a doctor and retired medical missionary who is currently a distinguished professor at Southwestern Baptist Theological Seminary. She spent 35 years in India working as a doctor and church planter, and she was an administrator and chief of the medical staff at Bangalore Baptist Hospital. She also oversaw the construction of the Rebekah Ann Naylor School of Nursing, served as a professor of anatomy and physiology at the school and helped plant 900 churches in the state of Karnataka, India, between 1999 and 2009.

Le Roux is the co-founder and CTO of ICON, a construction technology company that uses 3D printing, robotics, software and advanced materials to build houses. He invented the Vulcan printer a large-scale 3D printer designed for constructing homes and other structures.

Peters, who received the Pro Texana Medal of Service, is the founder and executive director of Unbound Global, a multi-national organization focused on combating human trafficking that is headquartered in Waco. She founded Unbound out of Antioch Community Church in 2012 after seeing the effects of human trafficking around the world. She also serves as chair on the Heart of Texas Human Trafficking Coalition, which she also co-founded in 2014.

Guerrero is a six-time Grammy award-winning conductor and music director of the Nashville Symphony. Born in Nicaragua, Guerrero has appeared with many prominent orchestras and symphonies around the world.

Scott is the founder and head of documentaries at Strategy Films and has won awards as a director. He began his career in politics before finding a passion for filmmaking. Scott has directed Shape of Shreveport, What About Waco, Class Action Park and most recently Ode to Joy, The Death and Resurrection of Baylor Basketball.

George is the second-ever recipient of the Merrie Beckham Alumni By Choice of the Year, which is given to someone who was previously nominated and selected as an Alumni By Choice and has achieved distinction through service to the community. Georges daughters attended Baylor, and George helped form the North Carolina Chapter of the Baylor Parents Network. George and her husband were named Baylor Parents of the Year in 2018.

Naylor said she was surprised and humbled to receive the Pro Ecclesia Medal of Service. She also said her time at Baylor prepared her well for both her medical and theological missions.

I consider it all a great privilege that God let me do that, Naylor said. Seeing people come to faith in Christ, of churches being started, of people being healed physically, meeting needs that otherwise might not have been met those are privileges. God has directed me as He promised to do. I have submitted my life to Him. He directed my path. This recognition is so appreciated, and I want to bring honor and glory to God, who just made all of it possible.

Link:
Recipients of 2022 Alumni Awards announced - The Baylor Lariat

Erin O’Hara: Current health and wellness trends for 2022 – Newstalk ZB

Erin is the co-founder, director, naturopath and yoga teacher at Golden Yogi. She holds a bachelor of science (physiology) and a bachelor of natural medicine.

Erin OHara joined Francesca Rudkin to discuss whether you should pay close attention to the current wellness trends or if you should treat them as a trial and evaluate the situation yourself.

Current health and wellness trends of 2022

- Sound healing

- Boosted beverages / Superfoods Mushroom powders, collagen, matcha, adaptogen herbs

- Wim hof / cold water therapy

- Wearable digital technology aura rings, fit bits, tracking sleep / stress

- Mindful drinking / low or no alcohol drinks and spirits

- Outdoor fitness

- Conscious eating / plant-based earring / anti-diet / reducetarian / flexitarianism

LISTEN ABOVE

Here is the original post:
Erin O'Hara: Current health and wellness trends for 2022 - Newstalk ZB

Senior Lecturer, Biomedicine job with UNIVERSITY OF SYDNEY | 278497 – Times Higher Education (THE)

About the opportunity

The School of Medical Sciences is seeking to appoint two Senior Lecturers. As a Senior Lecturer you will develop an active research program and teach across our undergraduate and post-graduate degrees, with a particular focus on core physiology or anatomy teaching. You will make a significant contribution to the research, education and administrative endeavors of the School of Medical Sciences while building your reputation towards becoming an authority in your area of research.

The School of Medical Sciences has recently restructured to create research themes including neuroscience, chronic diseases, education innovation, infection immunity and inflammation, molecular bioscience, musculoskeletal science, biomedical informatics and digital health.

As a Senior Lecturer you will:

About you

To keep our community safe, please be aware of our COVID safety precautions which form our conditions of entry for all staff, students and visitors coming to campus.

Pre-employment checks

Your employment is conditional upon the completion of all role required pre-employment or background checks in terms satisfactory to the University. Similarly, your ongoing employment is conditional upon the satisfactory maintenance of all relevant clearances and background check requirements. If you do not meet these conditions, the University may take any necessary step, including the termination of your employment.

EEO statement

At the University of Sydney, our shared values include diversity and inclusion and we strive to be a place where everyone can thrive. We are committed to creating a University community which reflects the wider community that we serve. We deliver on this commitment through our people and culture programs, as well as key strategies to increase participation and support the careers of Aboriginal and Torres Strait Islander People, women, people living with a disability, people from culturally and linguistically diverse backgrounds, and those who identify as LGBTIQ. We welcome applications from candidates from all backgrounds.

How to apply

Applications (including a cover letter, CV, and any additional supporting documentation) can be submitted via the Apply button at the top of the page.

If you are a current employee of the University or a contingent worker with access to Workday, please login into your Workday account and navigate to the Career icon on your Dashboard. Click on USYD Find Jobs and apply.

For a confidential discussion about the role, or if you require reasonable adjustment or support filling out this application, please contact Andria Bingham, Recruitment Operations, on 02 8627 8552 or by email toandria.bingham@sydney.edu.au

The University of Sydney

The University reserves the right not to proceed with any appointment.

Click to view the Senior Lecturer (Teaching and Research) position description for this role.

Applications Close

Monday 14 February 2022 11:59 PM

See original here:
Senior Lecturer, Biomedicine job with UNIVERSITY OF SYDNEY | 278497 - Times Higher Education (THE)

Billionaires Are Hiring Top Doctors, Nobel Prize Laureates to Help Them Live Forever – Observer

Jeff Bezos and Lauren Sanchez attend the 10th Annual LACMA Art+Film Gala presented by Gucci at Los Angeles County Museum of Art on November 06, 2021 in Los Angeles, California. Axelle/Bauer-Griffin/FilmMagic

When you have all the money in the world, are free from the burden of family and children, and have seen Earth from space, whats left to live for? For Jeff Bezos, the answer appears to be living longer, possibly forever.

The retired Amazon founder, who just turned 58 earlier this month, has assembled a team of top doctors and scientists to lead a startup he funded with a mission that sounds all too familiar in the age of the Metaverse and space colonization: to reverse the process of aging and therefore defy death.

The startup, called Altos Labs, came out of stealth mode on Wednesday with the announcement that it has tapped Hal Barron, the chief scientific officer and president of the British pharmaceutical giant GlaxoSmithKline (GSK), to be the companys CEO this summer. Barron has led GSKs research and development since 2018. His earlier career included various leadership roles at biotech giant Genentech and later its parent company, Roche.

Subscribe to Observers Business Newsletter

From 2014 to 2017, Barron served as the president of R&D at the longevity startup Calico Life Sciences, founded by Google cofounder Larry Page, whose business is very similar to that of Altos Labs, which focuses on cell reprogramming in order to restore cell health and resilience to reverse disease, injury, and the disabilities that can occur throughout life, according to a press release on Wednesday.

Altos Labs was incorporated in the U.S. and the U.K. last year by Richard Klausner, 70, who was the head of the National Cancer Institute in the U.S. The company said Wednesday that it had secured more than $3 billion in funding at launch. It didnt disclose who its investors are. Bezos has chipped in through his family investment office, Bezos Expeditions, and Russian-Israeli billionaire Yuri Milner, 60, has invested through a family foundation, according to MIT Technology Review, which reported on the companys work in September 2021.

The startup has enlisted multiple Nobel Prize laureates to serve as board directors. They include Shinya Yamanaka, the winner of the 2012 Nobel Prize in Physiology or Medicine for his work in stem cell research, Jennifer Doudna, the co-winner of the 2020 Nobel Prize in Chemistry for her role in developing the gene-editing tool CRISPR, Frances Arnold, who won the 2018 Nobel Prize in Chemistry for her work on enzymes engineering, and David Baltimore, a 1975 Nobel laureate in Physiology or Medicine.

Yamanaka, who is a professor at Japans Kyoto University, will also serve as Altos Labs senior scientific advisor to oversee research activities in Japan.

Altos Labs has operations in San Francisco, San Diego, and Cambridge in the U.K., with significant collaborations in Japan.

Altos seeks to decipher the pathways of cellular rejuvenation programming to create a completely new approach to medicine, one based on the emerging concepts of cellular health, Klausner said in a statement. Remarkable work over the last few years beginning to quantify cellular health and the mechanisms behind that, coupled with the ability to effectively and safely reprogram cells and tissues via rejuvenation pathways, opens this new vista into the medicine of the future.

Read the original here:
Billionaires Are Hiring Top Doctors, Nobel Prize Laureates to Help Them Live Forever - Observer

Future Solutions for Drug Resistance in HER2+ Breast Cancer – Targeted Oncology

In an interview with Targeted Oncology, Ron Bose, MD, MPH, discussed HER2 drug resistance, its impact on treatment, and how new research may help in the future.

For the treatment of HER2-positive breast cancer, 8 targeted therapies have been FDA approved and have successfully improved survival and responses rates for these patients, research shows. Drug resistance continues to be an issue, however, limiting the clinical benefit of therapies.

In a recent study that assessed resistance to HER2 tyrosine kinase inhibitors, investigators found utility in obtaining genomic data and using computer simulations ahead of treatment. Additionally, the presence of HER3 was identified as the potential cause of resistance to agents like neratinib (Nerlynx). The findings suggested that other HER2-expressing cancers may benefit from this information as well.

In an interview with Targeted Oncology, Ron Bose, MD, MPH, associate professor, Department of Medicine, Oncology Division, Molecular Oncology, Department of Cell Biology & Physiology, Washington University School of Medicine in St. Louis, discusses HER2 drug resistance, its impact on treatment, and how new research may help in the future.

TARGETED ONCOLOGY: How has drug resistance impacted the treatment of patients with HER2-positive breast cancer?

Drug resistance has impacted treatment in many ways. This is a problem with all targeted therapies, and we see this with our standard HER2-positive breast cancer where we've had to use additional drugs to target HER2. With HER2 mutations, resistance can manifest either as primary drug resistance, lack of response, or acquired drug resistance where the patients initially respond, and then the tumor starts to progress.

We know that HER2 mutations are one of many mutations that occur in patient with breast cancers, so that they're not occurring in isolation. They're not a solitary driver. They may be accompanied by changes in PI3 kinase mutations in p53, and other mutations. These can be acquired mutations in estrogen receptor. ESR1 and HER3 are found.

Also, in the study that we cited and commented on, investigators identified a HER3 kinase stimming mutation that enhances the ability of HER 3 dimerize with HER2. And this results in increased PI3 kinase signaling. What the investigators proposed was that this can be targeted by a combination of HER2 and PI3 kinase inhibitors. They tested neratinib plus alpelisib [Piqray].

What are the key takeaways from your analysis?

What motivated the study is there's been 3clinical trials focusing on HER2 indications. One is the SUMMIT trial, which is a basket trial of neratinib for HER2-postiive cancers. The next is the MUTER trial, which is a breast cancer-specific trial for HER2 mutations, and third is the British plasma MATCH trial, which is a circulating tumor DNA-based trial which included an arm for HER2-mutated breast cancer. In all of these cases, we're seeing evidence that median progression -free survival, when you're combining neratinib plus fulvestrant, is about five months. And so looking at mechanisms of resistance and looking at strategies to try to extend median PFS is going to be very important. The studies identified HER3 kinase domain mutations as a of drug resistance. They propose that apelisib would be a good strategy to overcome this drug resistance. And this would be a regimen that can move forward into a clinical trial.

Was there anything about this analysis that may be particularly of interest to community oncologists?

One thing that I found a novel for the study was their use of computer-based simulations for how these mutations affect protein structure and function. And as we're getting into, the evaluation and trying to figure out how to target more and more cancer mutations identified by next-generation sequencing, these computer simulations are very powerful because they can rapidly assess what is the consequence of these mutations? Are these mutations functionally silent? Or are these mutations functionally important? What impact do they have on protein function overall? So, these computer simulations are a very important direction. And as with so many things that are computer-based, the field of computer simulations of protein structured functions is really racing ahead, and it's something that oncologists might want to have some appreciation for, because I think we will see it more and more in future studies.

What is your best advice on how oncologists can delay or stop drug resistance for patients with HER2-positve breast cancer?

It is very complex. In the context of HER2 mutations, that is something that must be research in the clinical trial space right now. I think with regard to standard of care treatment options, trying to determine, when possible, what is the mechanism of drug resistance and what are available drugs that could overcome it is very helpful. So, I make use of ctDNA frequently in those situations, and do repeat biopsies whenever clinically feasible. Also, it can be very helpful when repeat biopsies are sent for NGS testing for PD-L1 expression. So, trying to understand the underlying biology and molecular changes in the cancer are ways of approaching the drug resistance. Its still a very challenging area. But it's something that in a large academic medical center, we're trying to make use of more and more.

What are your closing thoughts on this topic?

For clinicians, as they're looking at their patients on standard of care, consider sending ctDNA, consider repeat biopsy when feasible, and try to tie that with literature to make appropriate changes in the patient management.

Also, for the breast cancer and clinical trials communities, Id like to point out that HER2 mutations in breast cancer are very interesting drug target. There are exciting possibilities for HER2-mutated breast cancer. In particular, we're seeing an association with HER2 mutations and lobular breast cancer, which is a breast cancer for which we have fewer well-defined options. And targeting HER2-mutated lobular breast cancer is I think, going to be an opportunity for the future.

Reference:

Bose R, and Ma C. Breast Cancer, HER2 mutations, and overcoming drug resistance. N Engl J Med. 2021; 385(13):1241-1243. doi: 10.1056/NEJMcibr2110552

More here:
Future Solutions for Drug Resistance in HER2+ Breast Cancer - Targeted Oncology

Global Food Challenges Are At The Heart Of A New UCLA Center – LAist

Start your day with LAist

Sign up for the Morning Brief, delivered weekdays.

A $13.5 million donation to UCLA will go towards creating the UCLA Rothman Family Institute for Food Studies, with the goal of addressing global food challenges and practices.

The institute will bring together a range of experts and individuals, including faculty, staff, students, chefs and community members.

The program will seek to generate practical solutions, said Dr. Wendelin Slusser, a professor of community health sciences, in a statement.

The institute is looking at food from a system-based, interdisciplinary perspective to contribute to the health and well-being of the individual, community and the planet, she said.

By bringing together a wide range of experts, UCLA officials hope to broaden the scope of the institute's discoveries and perspective.

Some of these grand challenges we're facing in society, like issues with the planet and food access, are complex problems that really require experts from different topics, said biophysicist Amy Rowat, a professor of integrated biology and physiology at UCLA.

Research will be conducted over the next five years, but Rowat said there are plans to update the public in six months.

What questions do you have about Southern California?

Read more from the original source:
Global Food Challenges Are At The Heart Of A New UCLA Center - LAist

New Business Takes On Epidemic of Poor Posture and Spine Disorders – PR Web

Boise Chiropractor

BOISE, Idaho (PRWEB) January 24, 2022

A brand new chiropractic clinic and spine rehab facility, Optimal Spine & Posture, is now open and serving the Boise, ID communities. Optimal Spine & Posture not only specializes in posture, but an array of spine disorders including low back pain, neck pain, headaches and migraines, hyperkyphosis and scoliosis.

Optimal Spine & Posturesspine rehab and wellness center not only provides its patients with the most effective and reliable methods of treating musculoskeletal conditions, butthey strive to empowertheir patients with the knowledge and tools that allow them to protect themselves from future injury and to positively influence their own future state of healthand well-beingin the years to come.

The team at Optimal Spine & Posture is led by Dr. Justin Anderson, D.C. who is an advanced certified Chiropractic Biophysics clinician and diplomate. Chiropractic Biophysics or CBP is a biomechanically based technique system that uses a combined chiropractic and spinal rehabilitation approach. A graduate of Palmer College of Chiropractic in Davenport, IA, Dr. Justin has over 3,000 hours of post-doctorate coursework in clinical biomechanics and clinical study. As an advanced CBP diplomate, researcher, and instructor, Dr. Anderson now has two studies published in peer-reviewedmedicaljournals detailing the successesachieved in his practices.

At Optimal Spine & Posture our clinic encompasses aculturethatcultivateshealth, healing, and prosperity from the inside out.We consider total body health to provide a comprehensive understanding of biology, physiology, and body mechanics as it relates to your quality of life, says owner and clinic director Dr. Justin Anderson.

We put the health ofourpatients first, working to provide care that resolves the real problem and not merely the symptom,with theconsideration ofpreventative carein the future.We provide a friendly, high-energyatmosphere thatoffers ourpatients a warm,lovingenvironmentand provides them peace of mind in their healthcare decisions.

About Optimal Spine & Posture

Optimal Spine & Posture is the trusted leader in spine correction, an innovative force, where chiropractic meets advanced spine correction.

Specializing in neck and back pain, advanced spine correction, auto injury, scoliosis rehabilitation and scoliosis bracing, headaches and migraines.

At Optimal Spine & Posture there are treatment options for pain relief, spine correction and structural restoration, along with wellness care for those seeking to continue to function at optimal levels once their problem is corrected.

Optimal Spine & PostureAddress: 6744 N Glenwood St, Boise, ID 83714, United StatesPhone: +1 208-748-5909Website: https://optimalchiropracticboise.comBoise Chiropractor

Share article on social media or email:

See the original post:
New Business Takes On Epidemic of Poor Posture and Spine Disorders - PR Web